Enfuvirtide (T-20, Fuzeon): Research
- Clinical Trials Using Enfuvirtide (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Enfuvirtide (Regularly Updated)
From U.S. National Institutes of Health - HIV JournalView:Disappointing Results With Once-Daily Enfuvirtide (February/March 2006)
- HIV JournalView: Enfuvirtide: Is Needleless Dosing Possible? (February/March 2006)
- FDA Warns Roche About Misleading Comments Made by Salesperson Regarding Fuzeon (July 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Severe Enfuvirtide Injection Site Reactions Tied to Lack of Subcutaneous Fat (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Fuzeon (Enfuvirtide, T-20) Accelerated to Traditional Approval/Label Revisions (October 22, 2004)
From U.S. Food and Drug Administration - Fuzeon Recommended for CD4 Counts Over 100, Viral Loads Below 100,000 (October 2004)
Quick recap of recommendations published in the journal AIDS.
In HIV Treatment ALERTS!, from The Center for AIDS - HIV JournalView: Long-Term Resistance Patterns on Enfuvirtide (September 2004)
From The Body PRO - Enfuvirtide Benefits Persist for at Least 2 Years (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO - Global Guidelines Published on Enfuvirtide Use (May 18, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Drug Development News: Trimeris (May/June 2004)
Efforts are under way to improve the delivery method of T-20.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Enfuvirtide Safe and Effective for Adolescents (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - No Lipodystrophy Yet Seen With Regimens Including Enfuvirtide (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Enfuvirtide Benefits Confirmed at 48 Weeks (July 16, 2003)
Resistance testing is also found to be a reliable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America (March 13, 2003)
Results published early from the TORO-1 study investigating T-20 in treatment-experienced patients.
To read PDF, click here
In New England Journal of Medicine - Fuzeon Data Review (March 2003)
A capsule review of T-20 efficacy data from TORO 1 and TORO 2.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Baseline and On-Treatment Susceptibility to Enfuvirtide Seen in TORO 1 and TORO 2 to 24 Weeks (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Anti-HIV Drug Updates -- Three Drugs on the Near Horizon (January 2003)
Research from Barcelona on T-20, atazanavir and emtricitabine.
To read PDF, click here
In Project Inform Perspective, from Project Inform - Boulder Blues (January/February 2003)
Roche meets with ADAPs and activists to discuss T-20 (Fuzeon) pricing.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Informed Access to T-20 Planned (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis - Research From the 42nd ICAAC: T-20 License -- and Ultimate Trial -- Loom (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Study Shows T-20 Highly Effective as Regimen Booster (November 19, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Digging Deeper at the Resistance Workshop (August 14, 2002)
Key clinical findings from July's XI International HIV Drug Resistance Workshop.
From International AIDS Society - Long-Term Treatment With Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living (August 6, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Enfuvirtide in Combination With an Optimized Background Regimen vs. OB Alone in Patients With Prior Experience or Resistance to Each of the Three Classes of Approved Antiretrovirals (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO - T-20: Will Long-Term Use Weaken the Immune System's Ability to Fight HIV? (June 11, 2001)
From Canadian AIDS Treatment Information Exchange - Experimental Entry Inhibitor Drugs (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - A Controlled Phase II Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Low-Dose Ritonavir and Efavirenz in Non-Nucleoside-Naive Protease-Inhibitor-Experienced HIV-1 Infected Adults (February 8, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Forty-Eight Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO - T-20 After Barcelona Conference: Interview With Howard Grossman, M.D.
From AIDS Treatment News - The HIV/AIDS Drug Pipeline: Fusion Inhibitors (Summer/Autumn 2002)
From San Francisco AIDS Foundation
Clinical Management
Clinical Management
  |